Table 3.
ORS symptoms among the ORS-affected group and their severity
| ORS symptom | No. experiencing symptom (%) (total n = 9) | Median duration (range [days])a | No. (%) experiencing maximum severity of symptomsb |
||
|---|---|---|---|---|---|
| Mild | Moderate | Severe | |||
| Redness in both eyes | 4 (44) | 3 (2 to >21)c | 3 (33) | 1 (11) | 0 |
| Respiratory | |||||
| Coughing | 5 (56) | 4 (3–6) | 3 (33) | 2 (22) | 0 |
| Sore throat | 6 (67) | 3 (2 to >21)c | 3 (33) | 3 (33) | 0 |
| Hoarseness | 5 (56) | 4 (3–6) | 4 (44) | 1 (11) | 0 |
| Wheezing | 2 (22) | 4.5 (3–6) | 1 (11) | 1 (11) | 0 |
| Chest tightness | 7 (78) | 4 (2–7) | 5 (56) | 2 (22) | 0 |
| Difficult breathing | 1 (11) | 4 | 0 | 1 (11) | 0 |
| Difficulty swallowing | 3 (33) | 8 (2–17) | 0 | 3 (33) | 0 |
| ≥2 symptoms | 8 (89) | — | — | — | — |
| Facial swelling | |||||
| Lip swelling | 1 (11) | 2 | 0 | 1 (11) | 0 |
| Other swelling | 0 | — | — | — | — |
a
All cases had onset of symptoms 4 to 48 h after vaccination, as defined by the study protocol.
b
Mild, symptom(s) was present but did not interfere with daily activities; moderate, symptom(s) interfered with daily activities but did not prevent an individual from engaging in them; severe, symptom(s) prevented engagement in daily activities.
c
One subject had ongoing symptoms at 21 days postvaccination; the end date of those symptoms is unknown.